Detailed Information on Publication Record
2022
Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group
SCLAFANI, Francesco, Elisa FONTANA, Lucjan WYRWICZ, Anna Dorothea WAGNER, Juan W VALLE et. al.Basic information
Original name
Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group
Authors
SCLAFANI, Francesco (guarantor), Elisa FONTANA, Lucjan WYRWICZ, Anna Dorothea WAGNER, Juan W VALLE, Elizabeth SMYTH, Mark PEETERS, Radka OBERMANNOVÁ (203 Czech Republic, belonging to the institution), Cindy NEUZILLET, Manfred P LUTZ, Thibaud KOESSLER, Irit BEN-AHARON, Dirk ARNOLD, Maria ALSINA and Markus MOEHLER
Edition
CLINICAL COLORECTAL CANCER, DALLAS, CIG MEDIA GROUP, LP, 2022, 1533-0028
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 3.400
RIV identification code
RIV/00216224:14110/22:00128356
Organization unit
Faculty of Medicine
UT WoS
000898614900008
Keywords in English
Clinical trials; Meeting; Esophago-gastric cancers; Hepato-pancreatico-biliary cancers; Colorectal cancers
Tags
International impact, Reviewed
Změněno: 30/1/2023 12:51, Mgr. Tereza Miškechová
Abstract
V originále
Recently, we have witnessed impressive diagnostic and therapeutic changes for gastrointestinal cancer patients. New challenges brought by the COVID-19 pandemic have led us to re-evaluate our work priorities. Thanks to the commendable resilience of both investigators and patients, however, clinical research never stopped. In addition to conducting cutting-edge research and serving patients' needs, as EORTC Gastrointestinal Tract Cancer Group, we are committed to pursuing educational initiatives beneficial to the entire European oncology community and beyond. In this regard, we have been providing critical discussions of new data from major international meetings. In this article, we discuss results of important selected studies presented at the 2022 ASCO Gastrointestinal Cancer Symposium, putting them in perspectives and highlighting potential implications for routine practice. With the number of in-person attendees and practice-changing/informing trials presented, this meeting represented a milestone in the return to normality as well as in the fight against cancer.